GEM-333

N/A

Report date: 2026/03/19 16:52:35

Base Information

Drug NameGEM-333
Drug Alias NameGEM-333
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsCytotoxic T lymphocytes stimulantsAnti-Myeloid cell surface antigen CD33 +[4] 
TargetsT cell surface glycoprotein CD3Myeloid cell surface antigen CD33
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGemoab Monoconals
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAvenCell Europe GmbHBristol-Myers Squibb Company
Active IndicationsN/A
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A